Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

naxitamab-gqgk (Danyelza)

naxitamab-gqgk is an FDA-licensed reference biologic from Y-mABs Therapeutics, Inc.

351(a) biologicBLA 761171 Y-mABs Therapeutics, Inc
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2020

Reference product

Originator biologic
Ask AI
351(a)BLA 761171

Danyelza naxitamab-gqgk

Y-mABs Therapeutics, Inc

View full reference-product record
Approved
Marketing
Rx
Center
CDER
Patents
None listed

Exclusivity & patent cliffs

Protection horizon
Ask AI
  1. Reference approval

    Approval date of the reference naxitamab-gqgk product.

    6 yr 1 mo ago

  2. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    in 1 yr

naxitamab-gqgk: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for naxitamab-gqgk.

Related FDA reference tools

Assyro Intelligence

Ask anything about naxitamab-gqgk

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo